The multiple sets of data reflect the growing interest in our nerve repair products by surgeons across a variety of specialties, including those that perform nerve repair in the hand and upper extremities.” Erick DeVinney, AxoGen
Alachua, FL (PRWEB) October 03, 2013
AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced the presentation of data on AxoGen’s Avance® Nerve Graft in four presentations, including updated data from the RANGER® Registry presented in a poster and podcast, at the American Society for Surgery of the Hand (ASSH) 2013 Meeting, taking place October 3-6 in San Francisco.
The RANGER® Registry is an on-going, multi-center, utilization and outcomes study for Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve defects. The RANGER® Registry update will be presented by study investigator Wesley P. Thayer, M.D., Ph.D., Assistant Professor, Department of Plastic Surgery and Department of Orthopaedic Surgery at Vanderbilt University Medical Center.
Erick DeVinney, Director of Clinical and Translational Sciences at AxoGen, said, “We are thrilled that AxoGen has a robust presence at the ASSH 2013 meeting, including updated data from the landmark RANGER® Registry by the investigators and several physician presentations on nerve repair in the hand using our products. The multiple sets of data reflect the growing interest in our nerve repair products by surgeons across a variety of specialties, including those that perform nerve repair in the hand and upper extremities.”
AxoGen’s nerve repair products will be featured in the following lectures and poster presentations at the ASSH 2013 meeting:
- PodCast Poster Presentation: RANGER Updated Data Milestone From an Observational Registry Study Evaluating Outcomes from the Use of Processed Nerve Allografts
Presenter: Wesley Thayer, MD, PhD
Ongoing/available throughout meeting
Visit ASSH 2013 App to listen http://ativsoftware.com/appinfo.php?page=Now&project=ASSH13&ver=ep70
- Interactive Poster: Session 2 – Digital Nerve Repair with Processed Nerve Allograft
Presenter: Jeffrey Greenberg, MD
October 4, 12:00 – 12:45 p.m. PT
Room: Moscone 2018
- Poster Presentation: Allograft Nerve Reconstruction for Digital Nerve Loss
Presenter: John Taras, MD
October 5, 8:45 – 8:51 a.m. PT
Room: Moscone 3000
- Poster Presentation: Can Processed Nerve Allografts Provide Functional Motor Recovery in the Upper Extremities?
Presenter: Bauback Safa, MD, MBA, FACS
October 5, 8:55 – 9:01 a.m. PT
Room: Moscone 3000
In addition to these presentations, AxoGen’s products will be featured in several pre- and post-courses, the Company is sponsoring two educational forums (ASSH Interactive Forums 17 and 21), and the Company is exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 725.
Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve allograft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. For more information on AxoGen and its technology, please visit http://www.AxoGenInc.com. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and our ability to maintain the listing of our common stock on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the registration statement and the final prospectus.